Review article
Evaluation and rehabilitation of patients with adult motor neuron disease

https://doi.org/10.1016/S0003-9993(99)90089-8Get rights and content

Abstract

Adult motor neuron disease (amyotrophic lateral sclerosis [Als]) is a neurodegenerative disorder characterized by loss of motor neurons in the cortex, brain stem, and spinal cord, manifested by upper and lower motor neuron signs and symptoms affecting bulbar, limb, and respiratory musculature. Clinically, the disease course is characterized by progressive weakness, atrophy, spasticity, dysarthria, dysphagia, and respiratory compromise, ultimately resulting in death or mechanical ventilation in the vast majority of patients. Patterns of presentation and pathological features of the disease, along with clinical and electrophysiologic criteria for diagnosis, are discussed in this review. Since 8% to 22% of patients survive more than 10 years without ventilator use, meticulous medical and rehabilitation management is extremely important to ensure optimal health and quality of life in these patients. Major issues in the care of individuals with ALS include weakness and spasticity, impairments in activities of daily living and mobility, communication deficits and dysphagia in those with bulbar involvement, respiratory compromise, fatigue and sleep disorders, pain, and psychosocial distress. Research in ALS changes rapidly, but is currently focused on potential etiologic factors such as glutamate excitotoxicity, role of oxidative stress, autoimmunity to calcium channels, and cytoskeletal abnormalities, as well as related treatment initiatives including glutamate modulators, neurotrophic factors, antioxidants, antiapoptotic factors, and gene therapy. Recently, mutations in the gene encoding Cu/Zn superoxide dismutase were identified in a subset of familial ALS patients. Riluzole, a glutamate antagonist and Na-channel blocker, became the only drug currently approved for treatment of ALS after studies showed a small positive effect on survival. Until a definitive treatment or cure for ALS is found, the multifaceted rehabilitation team approach remains the best hope for improving health and survival in this devastating illness.

References (132)

  • DD Kilmer et al.

    The effect of a high resistance exercise program in slowly progressive neuromuscular disease

    Arch Phys Med Rehabil

    (1994)
  • RR Yeung

    The acute effects of exercise on mood state

    J Psychosom Res

    (1996)
  • WG Bradley

    Overview of motor neuron disease: classification and nomenclature

    Clin Neurosci

    (1996)
  • MJ Strong et al.

    Familial amyotrophic lateral sclerosis, 1850–1989: a statistical analysis of the world literature

    Can J Neurol Sci

    (1991)
  • JF Annegers et al.

    Incidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985–1988

    Arch Neurol

    (1991)
  • LJ Haverkamp et al.

    Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction

    Brain

    (1995)
  • AJ Hudson

    Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review

    Brain

    (1981)
  • JF Kurtzke

    Epidemiology of amyotrophic lateral sclerosis

    Adv Neurol

    (1982)
  • JM Belsh

    Epidemiology and historical perspective of ALS

  • T Tucker et al.

    Subacute reversible motor neuron disease

    Neurology

    (1991)
  • CP Tsai et al.

    Reversible motor neuron disease

    Eur Neurol

    (1993)
  • A Eisen et al.

    Duration of amyotrophic lateral sclerosis is age dependent

    Muscle Nerve

    (1993)
  • B Brownell et al.

    The central nervous system in motor neuron disease

    J Neurol Neurosurg Psychiatry

    (1970)
  • HJ Colmant

    Progressive bulbar palsy in adults

  • A Pestronk et al.

    Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies

    Ann Neurol

    (1990)
  • GJ Parry et al.

    Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease

    Muscle Nerve

    (1988)
  • CM Fisher

    Pure spastic paralysis of corticospinal origin

    Can J Neurol Sci

    (1977)
  • MF Beal et al.

    Primary lateral sclerosis: a case report

    Arch Neurol

    (1981)
  • CE Pringle et al.

    Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria

    Brain

    (1992)
  • El Escorial Workshop

    World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis

    J Neurol Sci

    (1994)
  • DR Rosen et al.

    Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

    Nature

    (1993)
  • A Plaitakis et al.

    Abnormal glutamate metabolism in amyotrophic lateral sclerosis

    Ann Neurol

    (1987)
  • JD Rothstein et al.

    Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis

    Ann Neurol

    (1990)
  • JD Rothstein et al.

    Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis

    N Engl J Med

    (1992)
  • RG Smith et al.

    Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis

    N Engl J Med

    (1992)
  • ES Louwerse et al.

    Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral scerosis

    Arch Neurol

    (1995)
  • DA Figlewicz et al.

    Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis

    Human Mol Genet

    (1994)
  • S Murayama et al.

    Immunohistochemical and ultrastructural studies of lower motor neurons in amyotrophic lateral sclerosis

    Ann Neurol

    (1990)
  • SS Gubbay et al.

    Amyotrophic lateral sclerosis: a study of its presentation and prognosis

    J Neurol

    (1985)
  • JM Belsh

    Clinical presentation and course of ALS

  • H Mitsumoto

    Diagnosis and progression of ALS

    Neurology

    (1997)
  • TL Munsat et al.

    The natural history of motoneuron loss in amyotrophic lateral sclerosis

    Neurology

    (1988)
  • WG Bradley et al.

    Morphometric and biochemical studies of peripheral nerves in amyotrophic lateral sclerosis

    Ann Neurol

    (1983)
  • PJ Dyck et al.

    Frequency of nerve fiber degeneration of peripheral motor and sensory neurons in amyotrophic lateral sclerosis

    Neurology

    (1975)
  • RA Radtke et al.

    Abnormal sensory evoked potentials in amyotrophic lateral sclerosis

    Neurology

    (1986)
  • JM Shefner et al.

    Abnormalities in the sensory action potential on patients with amyotrophic lateral sclerosis

    Muscle Nerve

    (1991)
  • RW Fincham et al.

    Sensory nerve conduction in amyotrophic lateral sclerosis

    Neurology

    (1964)
  • T Mannen et al.

    Preservation of a certain motor neuron group in the sacral cord in amyotrophic lateral sclerosis

    J Neurol Neurosurg Psychiatry

    (1977)
  • P Galassi et al.

    Cognitive impairment in motor neuron disease

    Acta Neurol Scand

    (1985)
  • M Poloni et al.

    Neuropsychological measures in amyotrophic lateral sclerosis and their relationship with CT scan-assessed cerebral atrophy

    Acta Neurol Scand

    (1986)
  • Cited by (80)

    • Motor neurone disease

      2018, Handbook of Clinical Neurology
      Citation Excerpt :

      Regular assessment by the multidisciplinary care team aims to identify deficits early to prevent falls by providing gait support and intervention in a timely manner (Dharmadasa et al., 2016). The main treatment objectives are to prolong independence in mobility and activities of daily living, prevent complications such as contractures and musculoskeletal pain, and maintain strength through an appropriate exercise program (Francis et al., 1999). This also allows patients and families to remain informed regarding safe and efficacious fall prevention strategies as the disease progresses.

    • Rehabilitation of motor neuron disease

      2013, Handbook of Clinical Neurology
    View all citing articles on Scopus

    No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated.

    View full text